INDICATION

EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis.

Please see below for Important Safety Information for EPCLUSA.

PATIENT SUPPORT MATERIALS

Thumbnail of EPCLUSA in-office brochure

EPCLUSA in-office brochure

A resource you can share with your patients highlighting HCV education, financial support options, and patient support.

Thumbnail of EPCLUSA brochure (en Español)vv

EPCLUSA brochure (en Español)

A resource in Spanish to share with your patients highlighting HCV education, financial support options, and patient support.

Thumbnail of EPCLUSA education line resource card

Education line resource card

A card with information about the EPCLUSA Education Line, including the contact number and a list of offerings.

Thumbnail of EPCLUSA real patient brochure

EPCLUSA real patient brochure

A resource you can share with your patients highlighting why real HCV patients are treated with EPCLUSA, what to expect from treatment, and how to get support with access and co-pay.